following a full submission:
buprenorphine (Buvidal®) is accepted for restricted use within NHSScotland.
Indication under review: Treatment of opioid dependence within a framework of medical, social and psychological treatment. Treatment is intended for use in adults and adolescents aged 16 years or over.
SMC restriction: Use in patients in whom methadone is not suitable and for whom the use of buprenorphine is considered appropriate.
In a phase III study in patients with opioid dependence, subcutaneous buprenorphine was non-inferior to sublingual buprenorphine/naloxone for the mean percentage of urine samples with test results negative for illicit opioids.
Medicine details
- Medicine name:
- buprenorphine (Buvidal)
- SMC ID:
- SMC2169
- Indication:
For the treatment of opioid dependence within a framework of medical, social and psychological treatment. Treatment is intended for use in adults and adolescents aged 16 years or over.
- Pharmaceutical company
- Camurus Ltd
- BNF chapter
- Central nervous system
- Submission type
- Full
- Status
- Restricted
- Date advice published
- 12 August 2019